Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light of competitors Biogen Inc (NASDAQ:BIIB) and Ionis Pharmaceuticals …
Following the news that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has secured FDA approval in a major way for its pipeline drug Spinraza in the indication …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced today that it has earned $5 million milestone payment from Janssen Biotech, Inc. (Janssen) associated with the validation …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced today that it has advanced its lead drug candidate IONIS-AZ4-2.5-LRx, which has now been renamed AZD8233, into preclinical …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and its wholly-owned subsidiary Akcea Therapeutics announced that the Phase 3 COMPASS study met its primary endpoint. COMPASS is …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced today that it has earned $28 million from AstraZeneca (NYSE:AZN) following AstraZeneca’s completion of IND-supporting studies and license …
Last week, Piper Jaffray analyst Joshua Schimmer hosted Richard Geary, Senior Vice President (SVP) of Ionis Pharmaceuticals Inc (NASDAQ:IONS), as well as Wade …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its third-quarter report today as well as offered a clinical update. In reaction, Cowen analyst Eric Schmidt notes …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) should be smiling after the company, along with Biogen (NASDAQ:BIIB), announced that SPINRAZATM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced positive data from a Phase 2 placebo-controlled study evaluating IONIS-FXIRx in patients with end-stage renal disease (ESRD) on …
